Home › Cancro ovarico › Arizona › Phoenix
Studi clinici su Cancro ovarico a Phoenix, AZ
11 studi su Cancro ovarico cercano partecipanti presso sedi a Phoenix e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
In reclutamentoStudio osservazionale
- Mayo Clinic, Phoenix
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
In reclutamentoFase 2
- Site 0143 - HonorHealth, Phoenix
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
In reclutamentoStudio osservazionale
- Mayo Clinic Hospital, Phoenix
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
In reclutamentoFase 3
- HonorHealth, Phoenix
A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
In reclutamentoFase 3
- Site 0107, Phoenix
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
In reclutamentoFase 3
- Cancer Center at Saint Joseph's, Phoenix
- Mayo Clinic Hospital in Arizona, Phoenix
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
In reclutamentoFase 1/2
- USOR HonorHealth, Phoenix
Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)
In reclutamentoFase 3
- Mayo Clinic Arizona, Phoenix
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
In reclutamentoFase 1/2
- Mayo Clinic Comprehensive Cancer Center, Phoenix
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
In reclutamentoFase 1/2
- Mayo Clinic, Phoenix
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
In reclutamentoFase 2
- Mayo Clinic Hospital, Phoenix
Studi su Cancro ovarico in altre città
- Houston, TX89 studi
- New York City, NY69 studi
- Boston, MA61 studi
- Los Angeles, CA50 studi
- Nashville, TN49 studi
- Arlington, VA46 studi
- Philadelphia, PA44 studi
- Columbus, OH39 studi
- St. Louis, MO38 studi
- Chicago, IL36 studi
- San Antonio, TX31 studi
- Cleveland, OH30 studi
Altri studi a Phoenix
- Cancro al seno25 studi
- Cancro colorettale25 studi
- Obesità22 studi
- Cancro metastatico20 studi
- Cancro del polmone non a piccole cellule20 studi
- Insufficienza cardiaca18 studi
- Cancro (tutti i tipi)17 studi
- Cancro alla prostata17 studi
- Malattie cardiovascolari16 studi
- Mieloma multiplo16 studi
- Cancro pancreatico16 studi
- Sovrappeso15 studi
Fonte: ClinicalTrials.gov, dati recuperati il 6 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.